| Autor: |
Ilerhunmwuwa, Nosakhare Paul, Adeniran, Olayemi, Inyang, Lawrence, Wasifuddin, Mustafa, Hakobyan, Narek, Perry, Jamal Christopher, Abdul Khader, Abul Hasan Shadali, Tahir, Muhammad, Wang, Jen Chin |
| Předmět: |
|
| Zdroj: |
European Journal of Haematology; Sep2023, Vol. 111 Issue 3, p441-448, 8p |
| Abstrakt: |
Introduction: The outcomes of pulmonary embolism (PE) in sickle cell disease (SCD) are poorly established in the literature. This study examined the prevalence and outcomes of patients with PE and SCD. Methods: The National Inpatient Sample was used to identify patients' data with a diagnosis of PE and SCD in the United States from 2016 to 2020 using the International Classification of Disease, 10th Revision codes. Logistic regression was used to compare outcomes between those with and without SCD. Results: Of the 405 020 patients with PE, 1504 (0.4%) had SCD, and 403 516 (99.6%) did not have SCD. The prevalence of PE with SCD was stable. Patients in the SCD group were more likely to be female (59.5% vs. 50.6%; p <.0001), Black (91.7% vs. 54.4%; p <.0001), with a lower rate of comorbidities. The SCD group had higher in‐hospital mortality (odds ratio [OR] = 1.41, 95% confidence interval [CI]:1.08–1.84; p =.012) but lower catheter‐directed thrombolysis (OR = 0.23, 95% CI: 0.08–0.64; p =.005), mechanical thrombectomy (OR = 0.59, 95% CI: 0.41–0.64; p <.0029), and inferior vena cava filter placement (OR = 0.47, 95% CI: 0.33–0.66; p <.001). Conclusion: In‐hospital mortality remains high in PE with SCD. A proactive approach, including maintaining a high index of suspicion for PE, is needed to reduce in‐hospital mortality. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
